STING agonist-1: High-Purity Small Molecule for STING Pathway Activation

Executive Summary: STING agonist-1 (B7835) is a well-characterized small molecule that activates the STING pathway, driving type I interferon production and facilitating studies of innate immunity (Zheng et al., 2025). Its high purity (≥98%, HPLC/NMR) supports reproducible results in immunology and inflammation models (APExBIO). STING agonist-1 is soluble in DMSO and stable at -20°C as a solid. It plays a critical role in research on cancer immunotherapy and B cell–mediated tertiary lymphoid structure (TLS) formation (AImmunity.com). The product's reliability is ensured by validated analytical data and strict shipping conditions.

Biological Rationale

The STING (Stimulator of Interferon Genes) pathway is a central component of the innate immune response. Activation of STING triggers the production of type I interferons and pro-inflammatory cytokines, which are critical for antiviral defense, tumor surveillance, and the orchestration of adaptive immunity (Zheng et al., 2025). Recent research implicates STING in the regulation of tertiary lymphoid structures (TLS), which are ectopic lymphoid formations associated with improved prognosis in several cancers, including esophageal squamous cell carcinoma (ESCC) (Zheng et al., 2025). B cell activation within TLS is regulated by IRF4, a transcription factor whose expression is upregulated by STING and CD40 signaling through TRAF2 and non-canonical NF-κB pathways.

STING agonist-1, with the chemical identity (Z)-4-(2-chloro-6-fluorobenzyl)-N-(furan-2-ylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carbimidic acid, is designed to mimic endogenous STING ligands and induce the pathway in vitro and in vivo (APExBIO). This enables the study of innate immune signaling and the development of innovative immunotherapeutic strategies.

Mechanism of Action of STING agonist-1

STING agonist-1 functions as a small molecule agonist of the STING protein, facilitating its conformational activation. Upon binding, STING translocates from the endoplasmic reticulum to the Golgi apparatus, initiating a phosphorylation cascade involving TBK1 and IRF3, ultimately resulting in the transcriptional activation of type I interferon genes (Zheng et al., 2025). In B cells, STING signaling converges with CD40-mediated pathways, both interacting with TRAF2 to upregulate IRF4. This upregulation is essential for B cell activation, proliferation, and TLS formation (Ruxolitinib-Phosphate.com). STING agonist-1 thus enables researchers to dissect the interplay between innate and adaptive immunity in controlled experimental settings.

Evidence & Benchmarks

• STING agonist-1 induces robust type I interferon production in primary immune cells and cell lines, validated by qPCR and ELISA assays (Zheng et al., 2025).
• B cell activation and IRF4 expression are significantly increased upon STING pathway stimulation, as shown in single-cell RNA-seq datasets and in vitro studies (Zheng et al., 2025).
• Competitive binding of CD40 and STING with TRAF2 drives non-canonical NF-κB signaling, leading to enhanced TLS formation in ESCC models (Zheng et al., 2025).
• High-purity STING agonist-1 (≥98%) ensures consistent activity and minimal off-target effects in cell-based assays (APExBIO).
• Product stability maintained at -20°C as a solid; solutions in DMSO are intended for immediate use only (APExBIO).

This article extends mechanistic insights beyond prior coverage at AImmunity.com by focusing on product-specific benchmarks and experimental reproducibility.

Applications, Limits & Misconceptions

STING agonist-1 is widely used as an immunology research reagent for dissecting the molecular basis of innate immune responses, inflammation, and cancer immunotherapy models. It is especially relevant for:

• Modeling type I interferon induction and signaling cascades in human and murine cell systems (Zheng et al., 2025).
• Investigating B cell-driven TLS formation and antitumor immunity (23-cgamp.com; this article provides a focused comparison of TLS-specific endpoints and product handling requirements).
• Elucidating non-canonical NF-κB pathway activation through competitive TRAF2 binding (AImmunity.com; here, we update the competitive context with recent benchmarking data).
• Screening and validation of immunotherapeutic agents targeting the STING pathway.

Common Pitfalls or Misconceptions

• STING agonist-1 is not recommended for long-term storage in solution; DMSO stocks must be used immediately to avoid loss of activity (APExBIO).
• The reagent is not a direct substitute for cyclic dinucleotides in all in vivo models; dose-response and species-specific signaling must be empirically validated.
• STING agonist-1 does not induce immune responses in STING-deficient cell lines or knockout models.
• Off-target effects may occur if used above recommended concentrations or with impure batches; always confirm purity and lot consistency.
• This product is intended for research use only and is not approved for diagnostic or therapeutic applications in humans or animals.

Workflow Integration & Parameters

STING agonist-1 (B7835) is supplied as a solid, with a MW of 430.88, and is readily soluble in DMSO for cell-based assays. It should be stored at -20°C to preserve stability and prevent degradation. Each batch is analyzed by HPLC and NMR, confirming ≥98% purity (APExBIO). Shipping is performed on blue ice to maintain compound integrity. For best results, prepare fresh DMSO solutions just prior to use, and avoid repeated freeze-thaw cycles.

Recommended concentrations for in vitro assays typically range from 0.1 to 10 µM, with optimal dosing established by pilot titration. Controls should include STING-deficient cells or pathway inhibitors to confirm specificity. Data reproducibility is supported by the product's certificate of analysis (CoA) and validated QC procedures. For further guidance on experimental design, refer to the comparative methodology outlined in 23-cgamp.com; this article details workflow integration, adding specific product-use recommendations.

Conclusion & Outlook

STING agonist-1, manufactured by APExBIO, is a key tool for activating the STING pathway in research settings. Its high purity, stability, and validated activity make it essential for studies of innate immunity, B cell activation, and cancer immunotherapy. Recent findings confirm its role in elucidating the mechanisms underlying TLS formation and IRF4-driven B cell responses (Zheng et al., 2025). As mechanistic understanding of STING signaling advances, STING agonist-1 will continue to support innovation in immunology and translational research.